



The reliable and effective oxygen-ozone therapy at a cross-roads with ozonated saline infusion and ozone rectal insufflation

This is the peer reviewed version of the following article:

Original:

Bocci, V., Zanardi, I., Borrelli, E., Travagli, V. (2012). The reliable and effective oxygen-ozone therapy at a cross-roads with ozonated saline infusion and ozone rectal insufflation. JOURNAL OF PHARMACY AND PHARMACOLOGY, 64(4), 482-489 [10.1111/j.2042-7158.2011.01427.x].

Availability:

This version is available <http://hdl.handle.net/11365/8259> since 2016-11-19T10:56:29Z

Publisher:

Pharmaceutical Press:1 Lambeth High Street, London SE1 7JN United Kingdom:011 44 1491 829272,

Published:

DOI:10.1111/j.2042-7158.2011.01427.x

Terms of use:

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)

Reliable and effective oxygen-ozone therapy at a crossroads with ozonated saline infusion and ozone rectal insufflation

Velio Bocci^a, Iacopo Zanardi^b, Emma Borrelli^c and Valter Travagli^b

^aDip. di Fisiologia, ^bDip. Farmaco Chimico Tecnologico and ^cDip. di Chirurgia e Bioingegneria, Università degli Studi di Siena, Siena, Italy

Keywords

drug safety; oxidative stress; oxygen-ozone therapy; reactive oxygen species; therapeutic ozone

Correspondence

Valter Travagli, Dip. Farmaco Chimico Tecnologico, Università degli Studi di Siena, Viale Aldo Moro 2, 53100 Siena, Italy.
E-mail: travagli@unisi.it

Received May 10, 2011

Accepted November 9, 2011

doi: 10.1111/j.2042-7158.2011.01427.x

Abstract

Objectives This review aims to highlight the advantages and safety of oxygen-ozone therapy (OOT) and to suggest ways to enhance its acceptance.

Methods The treatment of a herniated disk by injecting a gaseous oxygen-ozone mixture inside the nucleus pulposus is a great clinical success. However, the use of OOT lags for a number of reasons, including lack of standardization, the need for numerous treatments, lack of knowledge and even denial.

Results Anecdotally, several million treatments by OOT have been performed worldwide indicating its usefulness, mainly in peripheral arterial diseases and age-related macular degeneration. The scepticism that accompanies the systemic use of ozone can only be overcome by demonstrating the validity of OOT in controlled and randomized clinical trials. Cheaper and quicker methods, such as ozonating physiological saline with successive infusion as well as ozone rectal insufflations, are becoming popular, however, such alternative procedures are erratic, unstable and liable to be toxic, with deleterious consequences, and are likely to discredit the beneficial use of ozone.

Conclusions The approval of ozone in terms of both therapeutic efficacy and safety will depend on the results achieved by authoritative clinical trials.

Introduction

During the last decade, oxygen-ozone therapy (OOT) has slowly come of age and today it is used in many countries. This has come about as scientific studies have clarified the mechanism of action of ozone when it comes in contact with human blood and biological fluids. With the exception of pathologies such as decompression sickness, CO and smoke poisoning, severe blood-loss anaemia and gas gangrene, where hyperbaric oxygen therapy is extremely useful, OOT appears to be more beneficial than hyperbaric oxygen therapy in peripheral arterial diseases complicated by chronic ulcers,^[1] osteoradionecrosis, refractory osteomyelitis^[2] and necrotizing fasciitis.^[3] OOT originated in Germany in around 1970 but for many years was performed in an empirical fashion without knowing how ozone acted.^[4] As ozone is one of the most reactive oxidants ($E^\circ = +2.076V$), it seemed difficult to understand how it could be therapeutically useful. However, in recent years, the concepts of paradoxical pharmacology,^[5] hormesis^[6] and systems biology^[7] have become accepted. The ozone paradox has been clarified and all the

elicited biochemical reactions and pharmacokinetics of the generated compounds appear well within the realms of standard biochemistry, molecular biology and pharmacology.^[8,9] Indeed, among alternative approaches, OOT is well qualified to be accepted as a conventional medicine.

In Russia, Ukraine and Cuba, treatment with ozone is already a reality in public hospitals, but they have adopted doubtful administration modalities such as the infusion of ozonated saline or oxygen-ozone rectal insufflations of excessive amounts of gaseous ozone. These surrogates have been developed because they are inexpensive, rapid and applicable to thousands of patients every day. Owing to the uncertainty in both concentration and stability of crucial compounds, no regulatory agency will accept these procedures and this discredits OOT. The aims of this review were: (1) to pharmacologically evaluate both reliable and doubtful methods of ozone administration; (2) to establish precise rules for performing this therapeutic treatment; and (3) to briefly summarize the state-of-the-art medical use of ozone.

Reliable and Doubtful Methods of Ozone Administration

Classical oxygen-ozone therapy

OOT has two forms: major-OOT (M-OOT), involving 50–200 ml of human blood, and minor-OOT (m-OOT), involving about 5 ml of blood. In both cases, blood is treated with precise ozone dosages and then the ozonated blood is either intravenously infused back (M-OOT) or intramuscularly injected into the donor (m-OOT). M-OOT has the scope of modifying the biological response especially to restore and enhance the antioxidant capacity of patients affected by inflammatory and age-associated disease states including typical vascular diseases (stroke, chronic heart disease and peripheral arterial diseases),^[10] the dry form of macular degeneration,^[4] and insulin-resistant linked type 2 diabetes.^[11] The m-OOT is intended as an unspecific protein therapy causing physiological immune stimulation in patients with recurring viral infections such as herpes type I and II.^[4] Ozone should be generated only when necessary and no storage is possible. For this reason, ozone generators that are safe, reliable and reproducible are crucial. Ozone formation can mainly be achieved by corona discharge generators.^[12] An important point to be considered is the use of medical grade oxygen instead of air as the feed gas; in fact, since the latter contains about 78% nitrogen, variable amounts of highly toxic nitric oxide will be produced. When the gas mixture is added to blood (containing 1 ml of sodium citrate 3.8% per 9 ml of blood or, if possible, Ca-heparin, 20 IU/ml) both gases dissolve into the water of plasma but ozone is 10-fold more soluble than oxygen. The PaO₂ raises up to 400 mmHg but the hyperoxygenation is therapeutically negligible. The real drug is ozone which immediately reacts with either hydrosoluble antioxidants present in the plasma (uric acid is oxidized to allantoin, ascorbic acid to dehydroascorbate, glutathione (GSH) to oxidised GSH and methionine to the corresponding sulfoxide) and with polyunsaturated fatty acids bound to albumin to instantaneously give hydrogen peroxide and bioactive aldehydes such as 4-hydroxy-nonenal, 4-hydroxy-hexenal and 4-oxo-2-nonenal, which form an adduct with the Cys34 of albumin or with GSH for Michael addition. On the basis of a recent metabonomic study, the Cys34 of albumin does not appear to be oxidized to sulfenic acid by ozone within the therapeutic range of 15–80 µg/ml ozone per ml of blood.^[13] On the other hand, if a trace of anion superoxide is formed, it is also reduced to hydrogen peroxide. Moreover, depending on the ozone dose, other alkenals can react with the imidazole nitrogen of histidine or/and with the amine nitrogen of lysine,^[14] because each albumin molecule contains nine nucleophilic groups and represents the most important detoxifying molecule.^[15] Alkenals are also rapidly converted into the corresponding alcohols by alcohol dehydrogenase, aldehyde reductase and aldose reductase.^[16,17]

Moreover, another detoxifying pathway is via glutathionylation by GSH-S-transferase A4 which is specific for 4-hydroxy-nonenal.^[18] Within the therapeutic range, it has been shown that no lipid peroxidation of the erythrocytic membrane occurs.^[19] Potential lipid peroxide formed is rapidly reduced to hydroperoxide via peroxiredoxins and GSH peroxidases. Hence, within less than the canonical 5 min of mixing the blood with the gas phase, ozone has fully reacted and generated no more than 40 µM of H₂O₂ (in the case of an ozone concentration of 80 µg/ml) as typical reactive oxygen species and 1–3 µM of alkenals as typical LOP. But what is the fate of these two messengers? The H₂O₂ gradient formed between plasma and intracellular H₂O of blood cells is very transient because H₂O₂ easily passes through the cell membrane, but inside the cell its concentration is never greater than 10% of the extracellular one^[20,21] because it is quickly reduced to water by the abundant GSH and thioredoxin.^[22] Its intracellular half-life is around 10–30 s, and in plasma it is still less than 1 min. Moreover, intracellular H₂O₂ activates the following biochemical pathways in blood cells: (1) owing to a variable increase of 2,3-diphosphoglycerate, the oxyhaemoglobin curve shifts to the right and erythrocytes can deliver more oxygen to hypoxic tissue; (2) activation of nuclear factor $\kappa\beta$ in lymphocytes results in a mild immune stimulation due to up-regulation of the synthesis of several cytokines; and (3) release of platelet growth factors that appear to be useful for stimulating the healing process. Next, during infusion of ozonated blood, any free alkenal is either detoxified or excreted via bile or urine. Alkenals linked to Cys34 of albumin as adducts or glutathionylated come in contact with billions of endothelial and parenchymal cells with multiple biological effects: (1) enhanced release of NO and nitrosothiols following vasodilation; (2) up-regulation of heme-oxygenase I with release of CO and bilirubin, which displays vessel dilation and antioxidant activity; (3) up-regulation of antioxidant enzymes (superoxide dismutase, GSH peroxidase; GSH reductase; catalase; glucose-6-phosphate dehydrogenase), γ -glutamate cysteine ligase, γ -glutamyl-transferase and phase II enzymes. In-vitro studies have demonstrated that the translocation of NF-E2-related factor 2 into the nucleus activates the expression of antioxidant-responsive element-containing genes.^[23,24] Once the infusion of ozonated blood was completed in an age-related macular degeneration patient, the half-life of MDA was 4 min, demonstrating the efficiency of the catabolic system in eliminating aldehydic compounds.^[25] Experiments in progress have shown the crucial relevance of alkenals as the inducers of the antioxidant response or, in other words, the role of alkenals as the critical messengers of ozone. The precise sequence and the molecular pathway involved will soon be clarified and this appears to be the last step in scientifically clarifying OOT.

Anecdotally, the value of M-OOT as a biological response modifier has been shown by private physicians with millions of treatments being performed in all parts of the world during the last decade. A few deaths due to the direct intravenous injection of oxygen-ozone gaseous mixture have been recorded and this approach has been prohibited by the International Ozone Association since 1984.^[26] Ozone is the initial trigger but when it is used in precisely defined conditions, it generates two classes of messengers (reactive oxygen species and LOPs), which during their short lifetime activate several biochemical pathways without toxic effects. However, the final word will only come with the results of well-controlled, randomized clinical trials in suitable diseases.



Ozonated saline

In 1994 one of us (VB) tried to ozonate simple physiological saline (0.9% NaCl) by adding 250 ml of the oxygen-ozone gas mixture with an ozone concentration of 70 µg/ml (hence an ozone total amount of 17.5 mg) to 250 ml of saline in a glass bottle of 500 ml. After 2–3 min mixing, the ozonated saline was ready. When it was intravenously infused in the arm, it procured an initial phlebitis which receded after about 36 h. It was found that ozone induced a progressive formation of hydrogen peroxide and chemiluminescent effects, suggesting the generation of free radicals, possibly superoxide radical, singlet oxygen and residual ozone.^[27] Noxious agents such as H₂O₂ and a transitory formation of NaClO can easily irritate the endothelium. Moreover, the Fenton's reaction may occur because the saline solution may contain a trace of Fe²⁺, leading to the formation of hydroxyl radical, and subsequently of transient NaClO formation.^[28] The different ozone reactivity and disappearance both in the absence and in the presence of chloride ions are shown in Figure 1. In detail, the diagram reveals the increase of O₃ bubbled at 70 µg/ml concentration




Figure 1 Ozone solubility and disappearance profile both in the absence and in the presence of 0.9% sodium chloride.

(gas inflow 1.5 l/min) and the following decrease in 400 ml of either ultrapure water or physiological saline when ozone bubbling was stopped after 25 min. The absorbance values were measured every 2 min at $\lambda = 260$ nm. As expected, at an O₃ concentration of 10 µg/ml, the curves were very similar, even if absorbance values were considerably lower (unpublished data). In fact, apart from the actual reaction pathways of chloride ions in physiological saline (0.9% NaCl) by ozone, hypothetical hypochlorite as well as its oxidised species such as chlorate could be very irritating and noxious compounds, even at a concentration below the instrumental sensitivity limit. From 1995, in Russia, physicians started to use ozonated saline in hospitals in all patients, claiming that ozonated saline was clinically as effective as M-OOT. However, the saline was ozonated by bubbling an oxygen-ozone gas mixture with a very low ozone concentration (1–3 µg/ml) for 20 min. Apparently, in Russia they have too many patients, insufficient facilities to perform the M-OOT as well as the Health Authorities have adopted a 'laissez-faire' policy. To the best of our knowledge, a comparative analysis of the therapeutic efficacy between ozonated saline and M-OOT has never appeared in an international peer-reviewed scientific journal. The apparent lack of toxicity by using such a low concentration is reasonable because, at the infusion time, which is usually more or less delayed from preparation, 250 ml of ozonated saline may contain only 0.5 mg of residual ozone and H₂O₂ at a very low concentration (1–2 µM). Consequently, during the infusion these compounds will be readily neutralized by the wealth of antioxidants present in the circulating blood. Whether biochemical effects due to residual H₂O₂ and ozone will occur remains uncertain. The difference between these two procedures are summarized in Table 1. As the infusion of ozonated saline is very cheap, less time-consuming than M-OOT and quite remunerative for unscrupulous practitioners, physicians have also started to use it in some Western countries and it is likely that it will be extensively used in poor countries, possibly at a dangerous higher O₃ concentration. Indeed, Ikonomidis *et al.* have

Table 1 Conceptual and practical differences between major oxygen-ozone therapy and ozonated physiological saline

	M-OOT	OS
Volume	150–200 ml ^a	~250–500 ml ^b
Reaction sites	<i>Ex vivo</i> , in the glass container	<i>In vivo</i>
Biochemical effects	Reactive oxygen species, <i>ex vivo</i> alkenals, <i>ex vivo</i> and <i>in vivo</i>	<i>In vivo</i>
Average ozone dose	4–16 mg	0.75–1.5 mg

M-OOT, major oxygen-ozone therapy; OS, ozonated physiological saline.
^aUsual *ex-vivo* blood volumes with Na-citrate or heparin in an ozone-resistant glass bottle. ^bThe volume variability depends upon gender, flow rate and venous blood flow (the higher the flow, the lower the biochemical effect).

reported that they maintain the saline solution under a constant flow of O₃ during intravenous infusion but they warned that the maximum amount of O₃ daily administered is usually 4–5 mg and should never exceed 8–10 mg.^[29] In their publication they stated that ‘if we exceed these rates, the over coagulation syndrome starts’ and they strongly recommend that coagulation tests be performed before starting therapy. These warnings reinforce our preliminary objection to this approach. Moreover Foksinski *et al.* detected 8-oxodeoxyguanosine, typical oxidative DNA damage in lymphocytes of atherosclerotic patients after the infusion of ozonated saline, which is a worrying result never detected after M-OOT.^[30] It is clear that ozonation of saline is an unstable process because, if it is not promptly infused, O₃ totally decomposes in 60 min and therefore this preparation does not comply with the pharmacotherapeutic principle that requires stability and an exact knowledge of the constituents. Another problem is that commercial ozone generators differ and they often have a variable gas output (from 1 up to 3–5 l/min) and consequently the total amount of O₃ delivered can vary from 1- to 5-fold. Therefore some ozonetherapists, in the absence of a suitable preparation, may risk intoxicating the patient. Another disturbing factor is that blood flow in the cubital vein varies especially in women, with the consequence of an uncertain blood/H₂O₂-O₃ relationship, implying variable biooxidation. Thus, a further diffusion on the use of ozonated saline, although less dangerous than the direct intravenous infusion of O₂-O₃ that some practitioners of naturopathy still perform, does not represent an improvement and in any case it will be never accepted by the FDA or by EU health authorities.

Ozone rectal insufflation

Another route of administration of O₃ is the insufflation of an O₂-O₃ gaseous mixture into the rectum. In 1936, when Aubourg proposed the procedure,^[31] it appeared a reasonable application for treating chronic colitis and fistulae. Nowadays, it has been proposed to ‘treat’ many other diseases.^[32–40] The insufflation of a volume of 200–250 ml of gas into the rectum/colon at an O₃ concentration ranging from 5 to no more than 35 µg/ml can be precisely done, but the effective O₃ dose is unpredictable because of possible flatulence and the presence of a more or less abundant luminal content. Thus, it is clear that a significant fraction of the dose will be neutralized by faecal material. The residual O₃ dose will dissolve and be neutralized into the layer composed of glycocalix and mucoproteins covering the mucosa. O₃ instantly and fully reacts with these compounds, but only a fraction of LOPs will be absorbed by the mucosa and the H₂O₂ will be totally reduced. Moreover, in a recent study with rabbits, ozone colorectal applications induced changes in erythrocytes aggregation and fragility, but the real therapeutic effect on vascular

diseases, diabetes and cancer remains uncertain.^[40] Once again, while in Western countries many patients object to this route, in Cuba there are thousands of patients treated every day, and this rapid, inexpensive procedure has always adopted the administration of 200 ml O₂-O₃ mixture with an O₃ concentration of 50 µg/ml (O₃ dose: 10 mg).^[32] However, the O₃ concentration appears to be too high and during prolonged use may be mutagenic. As this route is so uncertain it should not be used in controlled clinical trials.

Acceptance by Orthodox Medicine: Some Impediments

The clinical use of ozone presents a number of controversies that can be summarized as follows. (1) The poor past use of ozone such as direct gaseous intravenous injections, now prohibited, and/or the use of unreliable ozone generators, now replaced by the latest generation which by photometric determination in real time allows measurement of the precise ozone concentration, the gas volume output, and hence the dose. The correct range of therapeutically useful ozone concentrations has been accurately determined and varies between 10 and 80 µg/ml (0.21–1.68 mM) of ozone per ml of blood. The axiom ‘start low, go slow’ represents the best criterion, suggesting that treatment begin with 20 µg/ml of ozone per ml of blood, slowly scaling up to 60–70 µg/ml throughout 15–20 sessions, which is suitable to induce an antioxidative response in any patient, as a sort of ozone tolerance. A metabonomic study did not show any change in the blood profile after treatment with oxygen or with 80 µg/ml.^[19] (2) It is unfortunate that ozone therapy is also used by unscrupulous and incompetent physicians who, besides using ozonated saline, mix ozone therapy with other complementary treatments. Moreover, the reliable photometric system, indispensable for the measurement of precise ozone concentrations, costs about €4000 and only a percentage of generators on the market have it. (3) The lack of sponsors and funds means that controlled and randomized clinical trials cannot be undertaken, which is a major obstacle. Thus, only small trials have been performed thanks to the goodwill of a few clinicians. Consequently, the application of ozone therapy in all public hospitals is still being delayed by prejudice, lack of knowledge, competition with pharmaceuticals and the disinterest of the health authorities such as the FDA in the USA and the EMA in Europe. However, in Russia, Ukraine and China many patients are treated with simplified, yet uncertain, ozone therapy methods. In the ‘Madrid Declaration on Ozone Therapy’, as approved by the International Scientific Committee of Ozonotherapy, a list of the therapeutic uses of ozone has been published.^[41] Obviously, the performance of appropriate clinical studies in the most relevant diseases showing the validity and lack of side-effects of ozone therapy is urgently needed.

Current State-of-the-Art

Results achieved in clinical trials

The most suitable pathology to be treated by ozone therapy is vascular disease. Most of the attention has been focused on peripheral obstructive arterial disease. A study performed between 1974 and 1980 in 152 patients showed the beneficial effects of M-OOT in comparison with pentoxifylline and prostanooids, without adverse effects.^[42] Also, Mattassi *et al.*^[43] ($n = 68$) and Romero Valdés *et al.*^[44] ($n = 60$) found an improvement in at least 44% and 35% of patients, respectively. Other trials (most of them in less than 20 patients),^[45–50] although showing a beneficial effect over established therapy, were performed with different ozone concentrations and schedules. The most recent trial was carried out in 28 patients randomized to receive either their own ozonated blood or a cycle of prostacyclin infusion.^[1] All the patients continued conventional treatments with statins, antihypertensive and antiplatelet aggregation drugs. Ozone therapy proved to be more effective and far less expensive than the prostanooid analogue in terms of pain reduction and improvement of quality of life, but treatment was carried out for only 7 weeks (14 treatments).

In general, it appears that the usual OOT performed for at least 4 months (32–48 treatments) and maintained thereafter with four treatments each month is considered the best treatment for peripheral obstructive arterial disease. Despite frequent venipuncture, patients are mostly compliant because they notice the benefits of the therapy and frequently report a feeling of wellness. On the contrary, an irrational procedure called Celacade, supported by many millions of dollars from Vasogen Inc. (Canada), consisted of exposing 10 ml of human blood to an oxygen/ozone gas mixture (ozone concentration 15.35 g/m³) delivered into the blood at a flow of 240 ml/min and UV light (253.7 nm) at a temperature of 42.5°C for about 20 min. The treated blood sample was removed from the system and immediately administered by intragluteal injection to the donor patient. Two treatments were given on consecutive days, followed by a third on Day 14. Subsequent treatments were given at 4-week (28 days) intervals for at least 22 weeks, for a total of eight injections. Such a procedure used an expensive device able to deliver an enormously toxic dose of ozone (107.5 mg per ml of blood) plus undetermined UV irradiation at 42.5°C.^[51] The final ozone dose is about 15 000-fold higher than the average ozone dose used in classical OOT and the extremely high oxidation of blood causes complete denaturation of blood components.^[13] This procedure was designed to establish a non-specific immunomodulation therapy in the hope of reducing the inflammatory process and the chronic oxidative stress present in vascular diseases. It has proved to be useless in two multicenter, randomized, double-blind, placebo-controlled studies (SIMPADICO and ACCLAIM trial) enrolling about

3000 patients with critical vascular pathologies. These trials have proved two things: the excessive dose of ozone is useless and the value of a wealthy sponsor.

So far, stroke and chronic heart failure have not received attention in spite of the fact that only 15% of patients with stroke can receive thrombolysis with alteplase. Millions of people suffer from ischaemic diseases, which represent the major cause of death worldwide. If orthodox medicine accepts OOT as an adjunct to conventional medication a marked leap forward will become noticeable.

Ozone treatment for the dry form of age-related macular degeneration

Throughout the world there are more than 30 million people searching for a therapy slowing the progress of age-related macular degeneration. However, ophthalmologists can only prescribe antioxidants and zinc, which are only minimally effective. Since 1995, almost 1000 patients with the dry form of age-related macular degeneration have been treated with OOT at the Siena Polyclinic (Italy) and three-quarters have shown an improvement of one to two lines on the visual acuity chart.^[4] Moreover, it is relevant that the disease does not progress during OOT. Although it induces a pleiotropic response, the main advantage with OOT is due to an increased delivery of oxygen to the retina, the bodily tissue with the highest oxygen consumption. It is worth noting that OOT is useless, even harmful, in the exudative form of age-related macular degeneration and in multigenic and progressive disorders.

Effects of clinical ozone in diabetes

Both diabetes type I and type II lead to vascular and neurological complications. Several anecdotal results have been reported suggesting a marked improvement in glycaemic control and reduction of oxidative stress. A debate on using OOT in diabetes for delaying complications and improving the quality of life has been proposed.^[11]

Use of ozone for herniated disks

The application of gaseous ozone in low-back pain due to a herniated disk has been accepted worldwide. Either the method consisting of a small injection (3–5 ml of an oxygen-ozone gaseous mixture with an ozone concentration of 30–35 µg/ml) directly into the centre of the intersomatic space corresponding to the disk herniation^[52] or the indirect method of injecting an oxygen-ozone mixture (5–10 ml at 20 µg/ml ozone concentration, the so-called ‘chemical acupuncture’) into the paravertebral muscles corresponding to the metamers of the herniated disk have a success rate of 80 and 73%, respectively.^[53] More than a million people have already benefited from these procedures.

Use of ozone and ozone derivatives as a topical treatment

The therapeutic efficacy of gaseous ozone and its derivatives for the healing of both cutaneous and mucosal infections remains to be demonstrated in controlled clinical studies. All these ozonated compounds are today used in a very empirical fashion and by private physicians or naturopaths. It is understood that ozone, under various formulations, can display a cleansing effect and act as a potent disinfectant able to practically kill all pathogens present in the skin and mucosal surfaces. Furthermore, the decomposition of ozone, by increasing the availability of oxygen in the ischaemic or inflamed tissues, has the additional advantage of improving local metabolism and the proliferation of tissues, essential for the eventual mucosal or/and cutaneous healing.^[54] Moreover, while some studies suggest a promising potential of ozone in dentistry, the clinical evidence for its application is not extensive. There is a need for well designed, double-blind randomised clinical trials with adequate sample size, limited or no loss of follow up, and carefully standardised methods of measurement and analysis in order to justify the routine use of gaseous ozone or ozonated water/compounds as a treatment modality for cutaneous and mucosal infections.^[55–59]

Rules for Performing Ozone Therapeutic Treatment

A summary of the ethical and legal issues concerning the therapeutic use of ozone has been published by the International Scientific Committee of Ozonotherapy.^[60] Briefly, the major points are: (1) only qualified physicians with a university degree specialization in ozone therapy can perform such therapeutic intervention; (2) OOT or other approaches must be carried out following the updated regulations; (3) only ozone generators with a precise photometer, gas pressure control, pure medical oxygen and unused ozone disposable

should be used; and (4) the clinic must have an appropriate system of gas elimination as indicated by the European Commission rules and this should be checked annually by a qualified person.

Conclusions

The chemical, biochemical, molecular and pharmacological parameters characterizing ozone therapy are now known and are within the parameters of orthodox medicine. With some limitations, OOT appears to be the optimal treatment in vascular diseases, age-related macular degeneration and possibly diabetes. However, this must be demonstrated with controlled, randomized clinical trials performed in accordance with the Declaration of Helsinki. This is problematic owing to lack of funds and the apparent disinterest of health authorities. Some recent ozone administration modalities such as ozonated physiological saline and ozone rectal insufflations, although inexpensive and quick to perform, do not comply with the pharmacotechnical criteria of consistency and stability required by international health authorities. Only physicians with a qualified university specialization can perform ozone therapy. With ozone therapy being practised in many countries, it is hoped that this review may be useful in correcting some distortions regarding its use and allow some progress in OOT.

Declarations

Conflict of interest

The Author(s) declare(s) that they have no conflicts of interest to disclose.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

References

- Di Paolo N *et al.* Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. *Int J Artif Organs* 2005; 28: 1039–1050.
- Ripamonti CI *et al.* Efficacy and safety of medical ozone (O₃) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: preliminary results of a phase I–II study. *Oral Oncol* 2011; 47: 185–190.
- Di Paolo N *et al.* Necrotizing fasciitis successfully treated with extracorporeal blood oxygenation and ozonation (EBOO). *Int J Artif Organs* 2002; 25: 1194–1198.
- Bocci V. *Ozone. A New Medical Drug.* Dordrecht: Springer, 2011.
- Bond RA. Is paradoxical pharmacology a strategy worth pursuing? *Trends Pharmacol Sci* 2001; 22: 273–276.
- Calabrese EJ, Baldwin LA. Hormesis: the dose-response revolution. *Annu Rev Pharmacol Toxicol* 2003; 43: 175–197.
- Ho RL, Lieu CA. Systems biology: an evolving approach in drug discovery and development. *Drugs R D* 2008; 9: 203–216.
- Bocci V *et al.* The ozone paradox: ozone is a strong oxidant as well as a medical drug. *Med Res Rev* 2009; 29: 646–682.
- Bocci V *et al.* Ozone acting on human blood yields a hormetic dose-response relationship. *J Transl Med* 2011; 9: 66.
- Bocci V *et al.* Ozone: a new medical drug in vascular diseases. *Am J Cardiovasc Drugs* 2011; 11: 73–82.
- Bocci V *et al.* Diabetes and chronic oxidative stress. A perspective based on the possible usefulness of ozone therapy.

- 1 *Diabetes Metab Syndr Clin Res Rev* 2011; 5: 45–49.
- 2
- 3 12. Motret O *et al.* The dependence of
4 ozone generation efficiency on param-
5 eter adjustment in a triggered dielectric
6 barrier discharge. *Ozone Sci Eng* 1998;
7 20: 51–66.
- 8 13. Travagli V *et al.* Effects of ozone blood
9 treatment on the metabolite profile of
10 human blood. *Int J Toxicol* 2010; 29:
11 165–174.
- 12 14. Groeger AL, Freeman BA. Signaling
13 actions of electrophiles: anti-
14 inflammatory therapeutic candidates.
15 *Mol Interv* 2010; 10: 39–50.
- 16 15. Aldini G *et al.* Mass spectrometric
17 characterization of covalent modifica-
18 tion of human serum albumin by
19 4-hydroxytrans-2-nonenal. *J Mass*
20 *Spectrom* 2006; 41: 1149–1161.
- 21 16. Poli G *et al.* 4-Hydroxynonenal: a
22 membrane lipid oxidation product of
23 medicinal interest. *Med Res Rev* 2008;
24 28: 569–631.
- 25 17. Awasthi YC *et al.* Regulation of
26 4-hydroxynonenal mediated signaling
27 by glutathione S-transferase. *Methods*
28 *Enzymol* 2005; 401: 379–407.
- 29 18. Engle MR *et al.* Physiological role of
30 mGSTA4-4, a glutathione S-transferase
31 metabolizing 4-hydroxynonenal: a
32 generation and analysis of mGsta4 null
33 mouse. *Toxicol Appl Pharmacol* 2004;
34 194: 296–308.
- 35 19. Travagli V *et al.* A physicochemical
36 investigation on the effects of ozone on
37 blood. *Int J Biol Macromol* 2007; 41:
38 504–511.
- 39 20. Antunes F, Cadenas E. Estimation of
40 H₂O₂ gradients across biomembranes.
41 *FEBS Lett* 2000; 475: 121–126.
- 42 21. Stone JR, Yang S. Hydrogen peroxide: a
43 signaling messenger. *Antioxid Redox*
44 *Signal* 2006; 8: 243–270.
- 45 22. Mendiratta S *et al.* Enzyme-dependent
46 ascorbate recycling in human erythro-
47 cytes: role of thioredoxin reductase.
48 *Free Radic Biol Med* 1998; 25: 221–
49 228.
- 50 23. Levonen AL *et al.* Cellular mechanisms
51 of redox cell signalling: role of cysteine
52 modification in controlling anti-
53 oxidant defences in response to elec-
54 trophilic lipid oxidation products.
55 *Biochem J* 2004; 378: 373–382.
24. Li W *et al.* Activation of Nrf2-
antioxidant signaling attenuates
NFkappaB-inflammatory response
and elicits apoptosis. *Biochem Pharma-
col* 2008; 76: 1485–1489.
25. Bocci V. Does ozone therapy normalize
the cellular redox balance? Implica-
tions for therapy of human immuno-
deficiency virus infection and several
other diseases. *Med Hypotheses* 1996;
46: 150–154.
26. Jacobs MT. Untersuchung uber zwish-
enfalle und typische komplikationen in
der ozon-sauerstofftherapie. *OzoNach-
richten* 1982; 5: 1–5.
27. Bocci V *et al.* Studies on the biological
effects of ozone: 7. Generation of
reactive oxygen species (ROS) after
exposure of human blood to ozone.
J Biol Regul Homeost Agents 1998; 12:
67–75.
28. Razumovskii SD *et al.* Mechanism and
kinetics of the reaction of ozone with
sodium chloride in aqueous solutions.
Kinet Catal 2010; 51: 492–496.
29. Ikonomidis S *et al.* New data regarding
the use of oxidative stress (ozone
therapy) in the former Soviet Union
countries. *Riv Ital Ossigeno Ozonoter-
pia* 2005; 4: 40–43.
30. Foksinski M *et al.* Evaluation of
8-oxodeoxyguanosine, typical oxida-
tive DNA damage, in lymphocytes of
ozone-treated arteriosclerotic patients.
Mutat Res 1999; 438: 23–27.
31. Aubourg P. Ozon in der chirurgie. *Mem*
Acad Chir 1940; 65: 1183–1192.
32. Carpendale MT *et al.* Does ozone
alleviate AIDS diarrhea? *J Clin Gastro-
enterol* 1993; 17: 142–145.
33. Martínez-Sánchez G *et al.* Therapeutic
efficacy of ozone in patients with dia-
betic foot. *Eur J Pharmacol* 2005; 523:
151–161.
34. Li LJ *et al.* Protective effects of medical
ozone combined with traditional
Chinese medicine against chemically-
induced hepatic injury in dogs. *World J*
Gastroenterol 2007; 13: 5989–5994.
35. Re L *et al.* Ozone therapy: clinical and
basic evidence of its therapeutic poten-
tial. *Arch Med Res* 2008; 39: 17–26.
36. Calunga JL *et al.* Ozone oxidative post-
conditioning in acute renal failure.
J Pharm Pharmacol 2009; 61: 221–227.
37. Guanche D *et al.* Effect of ozone/
oxygen mixture on systemic oxidative
stress and organic damage. *Toxicol*
Mech Methods 2010; 20: 25–30.
38. Zaky S *et al.* The effect of rectal ozone
on the portal vein oxygenation and
pharmacokinetics of propranolol in
liver cirrhosis (a preliminary human
study). *Br J Clin Pharmacol* 2011; 71:
411–415.
39. Bocci V *et al.* Important details to be
clarified about the effect of rectal ozone
on the portal vein oxygenation. *Br J*
Clin Pharmacol 2011; 72: 350–351.
40. Artis AS *et al.* The effects of colorectally
insufflated oxygen-ozone on red blood
cell rheology in rabbits. *Clin Hemorheol*
Microcirc 2010; 45: 329–336.
41. •• •• •• [http://www.isco3.org/
resources.html](http://www.isco3.org/resources.html) (accessed 4 October
2011).
42. Rokitanski O *et al.* Die ozontherapie
bei peripheren, arteriellen
Durchblutungs-strörungen; linik, bio-
chemische und blutgasanalytische
untersuchungen. Wasser IOA, Ozon-
Weltkongress; Berlin, 1981: 53–75.
43. Mattassi R *et al.* Terapia con ozono per
via parenterale nelle arteropatie oblit-
eranti periferiche: meccanismo bio-
chimico e risultati clinici. *G Chir* 1987;
VIII: 109–111.
44. Romero Valdés A *et al.* Ozone therapy
in the advanced stages of arteriosclero-
sis obliterans. *Angiologia* 1993; 45: 146–
148.
45. Sroczynski J *et al.* Clinical assessment
of treatment results for atherosclerotic
ischemia of the lower extremities with
intraarterial ozone injections. *Pol Tyg*
Lek 1992; 47: 964–966.
46. Turczynski B *et al.* Ozone therapy and
viscosity of blood and plasma, distance
of intermittent claudication and
certain biochemical components in
patients with diabetes type II and
ischemia of lower extremities. *Pol Tyg*
Lek 1991; 46: 708–710.
47. Coppola L *et al.* Oxygen-ozone therapy
and haemorheological parameters in
peripheral chronic arterial occlusive
disease. *Thromb Atheroscler* 1992; 3:
83–89.
48. Verrazzo G *et al.* Hyperbaric oxygen,
oxygen-ozone therapy, and rheologic

- parameters of blood in patients with peripheral occlusive arterial disease. *Undersea Hyperb Med* 1995; 22: 17–22.
49. Tylicki L *et al.* Beneficial clinical effects of ozonated autohemotherapy in chronically dialysed patients with atherosclerotic ischemia of the lower limbs: pilot study. *Int J Artif Organs* 2001; 24: 79–82.
50. van der Zee H, De Monte A. Ozone auto-haemotherapy in lower limb ulcerations. Proceedings of the 15th Ozone World Congress. London: Speedprint MacMedia Ltd (London), 2001: 148–157.
51. Torre-Amione G *et al.* Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. *Lancet* 2008; 371: 228–236.
52. Andreula CF *et al.* Minimally invasive oxygen-ozone therapy for lumbar disk herniation. *AJNR Am J Neuroradiol* 2003; 24: 996–1000.
53. Paoloni M *et al.* Intramuscular oxygen-ozone therapy in the treatment of acute back pain with lumbar disc herniation: a multicenter, randomized, double-blind, clinical trial of active and simulated lumbar paravertebral injection. *Spine* 2009; 34: 1337–1344.
54. Travagli V *et al.* Ozone and ozonated oils in skin diseases: a review. *Mediators Inflamm* 2010; 2010: 610418.
55. Travagli V *et al.* Topical applications of ozone and ozonated oils as anti-infective agents: an insight into the patent claims. *Recent Pat Antiinfect Drug Discov* 2009; 4: 130–142.
56. Valacchi G *et al.* Ozonated sesame oil enhances cutaneous wound healing in SKH1 mice. *Wound Repair Regen* 2011; 19: 107–115.
57. Lynch E. Evidence-based efficacy of ozone for root canal irrigation. *J Esthet Restor Dent* 2008; 20: 287–293.
58. Hauser-Gerspach I *et al.* Comparison of the immediate effects of gaseous ozone and chlorhexidine gel on bacteria in cavitated carious lesions in children in vivo. *Clin Oral Invest* 2009; 13: 287–291.
59. Azarpazhooh A, Limeback H. The application of ozone in dentistry: a systematic review of literature. *J Dent* 2008; 36: 104–116.
60. •• •• •• http://www.aepromo.org/declaracion_madrid/Madrid_declaracion.pdf (accessed 4 November 2011).



20



21

Toppan Best-set Premedia Limited	
Journal Code: JPHP	Proofreader: Mony
Article No: 1427	Delivery date: 7 December 2011
Page Extent: 8	

AUTHOR QUERY FORM

Dear Author,

During the preparation of your manuscript, the questions listed below have arisen. Please answer **all** the queries (marking any other corrections on the proof enclosed) and return this form with your proofs.

Query References	Query	Remark
1	AUTHOR: Please confirm that Correspondence is correct.	
2	AUTHOR: this is a review paper, please revise the abstract under the following sub headings: Objectives; Key Findings; Summary	
3	AUTHOR: abbreviations defined; please check	
4	AUTHOR: please define LOP	
5	AUTHOR: 2,3-DPG, HbO ₂ have been defined; please check	
6	AUTHOR: NFkB has been defined; please check	
7	AUTHOR: abbreviations defined; please check	
8	AUTHOR: abbreviation GSH-Road has been changed to glutathione reductase; is this correct?	
9	AUTHOR: please define MDA; malonyldialdehyde?	
10	AUTHOR: some headings have been revised for clarity and structure; please check and amend if necessary	
11	AUTHOR: unsupported comment; consider deleting or revise	
12	AUTHOR: please clarify this sentence ' <u>afurtherdiffusion</u> on the use of ozonated saline ... '	
13	AUTHOR: 'Precise Rules for Performing Ozone Therapeutic Treatment Which are the impediments obstructing the use of ozone for being accepted by official medicine?' These headings have been heavily edited; please ensure that you are happy with the changes and amend if necessary	
14	AUTHOR: the heading 'Rules for Performing Ozone Therapeutic Treatment' has been moved to the section covering ethical and legal issues; please ensure that you are happy with the change and amend if necessary	
15	AUTHOR: 80 µg/ml of what? ozone?; please check	
16	AUTHOR: <u>referencesarerequiredforSIMPADICOandACCLAIMtrialsshowing lackofeffectofCelacade</u>	

1
3
4
5
6
8
10
11
12
14
15
16
17
19
20

17	AUTHOR: this heading has been moved here to replace the heading 'Ethical and legal issues concerning the therapeutic use of ozone'; please ensure that you are happy with the change and amend if necessary	
18	AUTHOR: funding statement added; please confirm that this is okay	
19	AUTHOR: Please supply the authorship and the year of publication for Reference 41.	
20	AUTHOR: Please check all website addresses and confirm that they are correct. (Please note that it is the responsibility of the author(s) to ensure that all URLs given in this article are correct and useable.)	
21	AUTHOR: Please supply the authorship and the year of publication for Reference 60.	


UNCORRECTED PROOF

USING e-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION


Required software to e-annotate PDFs: Adobe Acrobat Professional or Adobe Reader (version 8.0 or above). (Note that this document uses screenshots from Adobe Reader X)

The latest version of Acrobat Reader can be downloaded for free at: <http://get.adobe.com/reader/>

Once you have Acrobat Reader open on your computer, click on the [Comment](#) tab at the right of the toolbar:



This will open up a panel down the right side of the document. The majority of tools you will use for annotating your proof will be in the [Annotations](#) section, pictured opposite. We've picked out some of these tools below:



1. Replace (Ins) Tool – for replacing text.




Strikes a line through text and opens up a text box where replacement text can be entered.

How to use it

- Highlight a word or sentence.
- Click on the [Replace \(Ins\)](#) icon in the Annotations section.
- Type the replacement text into the blue box that appears.

standard framework for the analysis of microeconomics. Nevertheless, it also led to the emergence of strategic behavior in the number of competitors in the industry. This is that the structure of the industry, which led to the emergence of strategic behavior, are exogenous to the industry. Important works on this by Shirasaka (henceforth) we open the 'black b



2. Strikethrough (Del) Tool – for deleting text.



Strikes a red line through text that is to be deleted.

How to use it

- Highlight a word or sentence.
- Click on the [Strikethrough \(Del\)](#) icon in the Annotations section.

there is no room for extra profits and the number of competitors are zero and the number of competitors (net) values are not determined by the number of firms. Blanchard and ~~Kiyotaki~~ (1987), perfect competition in general equilibrium. The effects of aggregate demand and supply in the classical framework assuming monopoly power are an exogenous number of firms

3. Add note to text Tool – for highlighting a section to be changed to bold or italic.



Highlights text in yellow and opens up a text box where comments can be entered.

How to use it

- Highlight the relevant section of text.
- Click on the [Add note to text](#) icon in the Annotations section.
- Type instruction on what should be changed regarding the text into the yellow box that appears.

dynamic responses of mark-ups consistent with the VAR evidence

sation... y Ma... and... on n... to a... on... stent also with the demand-



4. Add sticky note Tool – for making notes at specific points in the text.



Marks a point in the proof where a comment needs to be highlighted.

How to use it

- Click on the [Add sticky note](#) icon in the Annotations section.
- Click at the point in the proof where the comment should be inserted.
- Type the comment into the yellow box that appears.

and supply shocks. Most of the... number of... standard framework... cy. Nevertheless, it also led to the emergence of strategic behavior in the number of competitors and the impact is that the structure of the sector



USING e-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION


5. Attach File Tool – for inserting large amounts of text or replacement figures.



Inserts an icon linking to the attached file in the appropriate place in the text.

How to use it

- Click on the [Attach File](#) icon in the Annotations section.
- Click on the proof to where you'd like the attached file to be linked.
- Select the file to be attached from your computer or network.
- Select the colour and type of icon that will appear in the proof. Click OK.



6. Add stamp Tool – for approving a proof if no corrections are required.



Inserts a selected stamp onto an appropriate place in the proof.

How to use it

- Click on the [Add stamp](#) icon in the Annotations section.
- Select the stamp you want to use. (The [Approved](#) stamp is usually available directly in the menu that appears).
- Click on the proof where you'd like the stamp to appear. (Where a proof is to be approved as it is, this would normally be on the first page).

of the business cycle, starting with the
 on perfect competition, constant ret
 production. In this environment goods
 extra profits and the market for marke
 he market for goods is determined by the model. The New-Key
 otaki (1987), has introduced produc
 general equilibrium models with nomin
 and market-clearing. Most of this literat




7. Drawing Markups Tools – for drawing shapes, lines and freeform annotations on proofs and commenting on these marks.


Allows shapes, lines and freeform annotations to be drawn on proofs and for comment to be made on these marks..

How to use it

- Click on one of the shapes in the [Drawing Markups](#) section.
- Click on the proof at the relevant point and draw the selected shape with the cursor.
- To add a comment to the drawn shape, move the cursor over the shape until an arrowhead appears.
- Double click on the shape and type any text in the red box that appears.



For further information on how to annotate proofs, click on the [Help](#) menu to reveal a list of further options:



MARKED PROOF

Please correct and return this set

Please use the proof correction marks shown below for all alterations and corrections. If you wish to return your proof by fax you should ensure that all amendments are written clearly in dark ink and are made well within the page margins.

<i>Instruction to printer</i>	<i>Textual mark</i>	<i>Marginal mark</i>
Leave unchanged	... under matter to remain	Ⓟ
Insert in text the matter indicated in the margin	∧	New matter followed by ∧ or ∧ [Ⓢ]
Delete	/ through single character, rule or underline or ┌───┐ through all characters to be deleted	Ⓞ or Ⓞ [Ⓢ]
Substitute character or substitute part of one or more word(s)	/ through letter or ┌───┐ through characters	new character / or new characters /
Change to italics	— under matter to be changed	↙
Change to capitals	≡ under matter to be changed	≡
Change to small capitals	≡ under matter to be changed	≡
Change to bold type	~ under matter to be changed	~
Change to bold italic	≈ under matter to be changed	≈
Change to lower case	Encircle matter to be changed	≡
Change italic to upright type	(As above)	⊕
Change bold to non-bold type	(As above)	⊖
Insert 'superior' character	/ through character or ∧ where required	Υ or Υ under character e.g. Υ or Υ
Insert 'inferior' character	(As above)	∧ over character e.g. ∧
Insert full stop	(As above)	⊙
Insert comma	(As above)	,
Insert single quotation marks	(As above)	ʹ or ʸ and/or ʹ or ʸ
Insert double quotation marks	(As above)	“ or ” and/or ” or ”
Insert hyphen	(As above)	⊥
Start new paragraph	┌	┌
No new paragraph	┐	┐
Transpose	┌┐	┌┐
Close up	linking ○ characters	Ⓞ
Insert or substitute space between characters or words	/ through character or ∧ where required	Υ
Reduce space between characters or words		↑